EP2421381A1 - Produit laitier induisant la satiété - Google Patents

Produit laitier induisant la satiété

Info

Publication number
EP2421381A1
EP2421381A1 EP10714380A EP10714380A EP2421381A1 EP 2421381 A1 EP2421381 A1 EP 2421381A1 EP 10714380 A EP10714380 A EP 10714380A EP 10714380 A EP10714380 A EP 10714380A EP 2421381 A1 EP2421381 A1 EP 2421381A1
Authority
EP
European Patent Office
Prior art keywords
whey
cmp
milk product
weight ratio
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10714380A
Other languages
German (de)
English (en)
Inventor
Cornelis Glas
Luutsche Van Der Zee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FrieslandCampina Nederland BV
Original Assignee
Friesland Brands BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Friesland Brands BV filed Critical Friesland Brands BV
Publication of EP2421381A1 publication Critical patent/EP2421381A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/09—Other cheese preparations; Mixtures of cheese with other foodstuffs
    • A23C19/0921—Addition, to cheese or curd, of minerals, including organic salts thereof, trace elements, amino acids, peptides, protein hydrolysates, nucleic acids, yeast extracts or autolysate, vitamins or derivatives of these compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/068—Particular types of cheese
    • A23C19/076—Soft unripened cheese, e.g. cottage or cream cheese
    • A23C19/0765—Addition to the curd of additives other than acidifying agents, dairy products, proteins except gelatine, fats, enzymes, microorganisms, NaCl, CaCl2 or KCl; Foamed fresh cheese products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to the field of functional foods.
  • it relates to whey proteins and the use thereof in (milk-based) compositions for body weight management.
  • HP diets have shown to induce weight loss and weight maintenance after a weight loss period.
  • DIT diet-induced thermogenesis
  • whey protein consistently resulted in the greatest food intake suppression relative to control, sucrose as well as in comparison with other protein sources such as egg albumin and soy protein.
  • the effect of whey was attributed to several aspects of whey metabolism. Briefly, whey compared with casein digests quickly and provides a rapid increase in plasma amino acids that is sustained for more than 2 hours and which may contribute to food intake suppression through increased brain amino acid concentrations. Also, whey ingestion results in the release of gut peptide hormones, such as cholecystokinin (CCK), involved in satiety induction.
  • CCK cholecystokinin
  • WO2007/042341 relates to a composition and method for providing nutritional support to obese patients.
  • the composition comprises a protein source which comprises at least 30% by weight of whey protein and which provides at least 30% of the total calories of the composition.
  • the role of whey proteins in food intake regulation was recently reviewed by Luhovyy et al. ( J. of the American College of Nutrition, Vol. 26, No. 6, 704S-712S (2007)).
  • Whey protein is the collection of globular proteins that can be isolated from whey, a by-product of cheese manufactured from cow's milk. It is typically a mixture of beta-lactoglobulin ( ⁇ 65%), alpha- lactalbumin ( ⁇ 25%), and serum albumin ( ⁇ 8%), which are soluble in their native forms, independent of pH. Casein macropeptide (hereinafter: CMP) is present in significant quantities (between 15 and 25%) in whey from cheeses made by rennet coagulation. Studies were performed to elucidate the role of individual whey proteins in weight management.
  • CMP Casein macropeptide
  • CMP in particular has been suggested to be the important component of whey proteins with respect to the satiety inducing effect based on the observation that CMP is a strong stimulant of CCK production in rats.
  • WO/2001/062086 relates to nutritional intervention composition taken before or during a meal for enhancing and extending post meal satiety by stimulating CCK.
  • the dry nutritional composition includes protein, casein macropeptide or glycomacropeptide, long chain fatty acids, soluble and/or insoluble fibers.
  • TRP amino acid tryptophan
  • beta-lactoglobulin A role for beta-lactoglobulin is suggested in patent application FR 2889067-Al, which relates to the use of a whey protein fraction comprising at least 5-fold excess (by weight) of beta-lactoglobulin over a-LA for reducing body mass. It is suggested the whey fraction can reduce the assimilation of fatty matter.
  • whey proteins have potential as functional food component for person with obesity, but that the relative and absolute contribution of individual whey proteins remains to be elucidated.
  • the present inventors therefore set out to gain further insights into the role of individual whey components in the regulation of body weight, in particular diet-induced thermogenesis and satiety induction. It was surprisingly found that the relative weight ratio between a-LA and CMP was found to be a relevant determinant in suppressing hunger and increasing energy expenditure. For example, an enhanced satiating effect can be observed with a whey protein fraction that is depleted in CMP and at the same time enriched with a-LA.
  • the invention provides the use of a whey fraction comprising a-LA and CMP, wherein the weight ratio between a-LA and GMP is at least 2, for the manufacture of a nutritional, dietary or pharmaceutical composition for promoting a healthy body weight.
  • the weight ratio a-LA to CMP is at least 3, for example 3.5, 3.6, 3.7 or even higher like at least 4.
  • the upper limit of the ratio is not critical although the a-LA/CMP ratio will typically be below 50, like up to 20 or 10.
  • casein macropeptide is meant to refer to the hydrophilic, soluble protein fragment released from bovine kappa-casein (K- casein) by chymosin, the predominant enzyme in calf rennet used in cheese making.
  • CMP is also referred to in the art as glycomacropeptide (GMP) due to its high carbohydrate content, or as casein-derived peptide (CDP).
  • GMP glycomacropeptide
  • CDP casein-derived peptide
  • CMP is a heterogeneous group of peptides having the same peptide length (64 amino acids) but variable carbohydrate and phosphorus contents.
  • the CMP homologue free of carbohydrate constitutes a large part of the CMP fraction.
  • the term CMP as used in the present invention covers different peptides with or without carbohydrate moieties.
  • the expression "for promoting a healthy body weight” refers to any contribution to obtaining or maintaining a non-obese body weight of a subject, preferably a human subject. It may involve promoting weight loss, preventing weight gain, reducing food intake, reducing adipocyte mass, increasing energy expenditure, improving the equilibrium between lean and fatty tissue, and combinations thereof.
  • the healthy human weight range widely used by doctors is based on a measurement known as the body mass index (BMI).
  • BMIs are classified in four categories and according to level of body weight and as follows: A BMI of less than 20 - Underweight; over 20 to 25 - Desirable or healthy range; over 25-30 - Overweight; over 30-35 - Obese (Class I); over 35- 40 - Obese (Class II); over 40 - Morbidly or severely obese (Class III).
  • the invention provides the use of the specific whey fraction to achieve or maintain a BMI between 20-35, preferably 20-30.
  • DIT diet-induced thermogenesis
  • satiety or a combination thereof.
  • DIT refers to the increase in heat production by the body after eating. It is due to both the metabolic energy cost of digestion (the secretion of digestive enzymes, active transport of nutrients from the gut, and gut motility) and the energy cost of forming tissue reserves of fat, glycogen, and protein. It can be up to 10-15% of the energy intake.
  • the whey fraction for use in the present invention typically has a total protein content of 35% to 80%, preferably 70% to 77%.
  • the whey fraction may comprise hydrolyzed whey proteins.
  • the a-LA content can vary but will generally range from about 20% to 40%, preferably 25-35 %.
  • the CMP content is significantly lower, and typically represents 1% to 15% of total protein.
  • Other whey proteins may of course also be present, such as beta-lac, lactoferrin, serum albumin, lysozyme, immunoglobulins.
  • the whey fraction is further characterized by: (a) a lactose content of 10% or less; (b) a total protein content of 12.5% to 95%; (c) a fat content of 15% or less; and / or (d) an ash content of 4.5% or less.
  • a whey protein fraction for use in the present invention can be readily achieved by methods known in the art.
  • WO99/188808 discloses a process for producing a whey protein concentrate substantially depleted in CMP which comprises adjusting the whey to a pH greater than about 4, contacting the whey with an anion exchanger to yield a bound whey fraction enriched in CMP and an unbound whey protein fraction depleted in CMP. After concentration and drying, this fraction is a powdered whey protein concentrate (WPC) depleted in CMP.
  • WPC powdered whey protein concentrate
  • the whey fraction for use in the present invention is depleted in CMP and supplemented with a-LA.
  • a-LA rich whey protein products are often used because of their high tryptophan content.
  • synthetic infant formula based on cow's milk (relatively low in a-LA) can be 'humanised' using cow's milk protein fraction having a high bovine a-LA content.
  • the high tryptophan and cystein content, together with a low methionine content of a-LA results in an overall amino acid composition more closely resembling that of human milk.
  • the manufacture of a-LA rich whey products is known in the art. Older techniques are generally based on lowering of the pH, leading to coagulation of a-LA.
  • EP0604684 discloses a process for the recovery of alpha - lactalbumin and/or beta -lactoglobulin enriched whey protein concentrate from a whey protein product, involving incubating a solution comprising said whey protein product with a calcium-binding ionic exchange resin in its acid form to initiate the instabilization of a-LA. More recent technologies for isolating a-LA involve membrane filtration. Cheang et al. (2003 Wiley Periodicals, Inc.
  • EP0311283 relates to a process for producing an a-LA-enhanced fraction from a liquid containing whey protein including a-LA and beta -lactoglobulin characterised by the step of subjecting the said liquid to ultrafiltration using a membrane having a molecular weight cut off of substantially 100,000.
  • a highly suitable source of a-LA for practicing the present invention is known under the tradename VivinalTM-Alpha (Borculo Domo Ingredients), which has a relatively high alpha-lactalbumin content and a low beta- lactoglobulin content. Thanks to it typical amino acid composition, it is widely used for the production of an infant nutrition resembling human milk more closely.
  • the a-LA/CMP weight ratio of Vi vinalTM- alpha is about 3.7.
  • the invention so concerns the application of a whey fraction enriched in a-LA but depleted in CMP in food products, like yoghurt, to induce an improvement in satiation together with an increase in energy expenditure.
  • the invention herewith provides an economically attractive nutraceutical which does not require the use of highly purified, and therefore expensive, a- LA as protein source.
  • it relates to a milk product comprising a whey fraction comprising a-LA and CMP, wherein the weight ratio between a-LA and GMP is > 2.
  • CMP is known to be a suppressor of gastric acid secretion and has been used an an anti-ulcer agent.
  • a-LA requires a pH value below about 3.5 in the stomach for an optimal digestion process and, hence, liberation of satiety-inducing peptides into the blood stream.
  • the present inventors postulate that a low relative CMP content contributes to an acidic environment, thereby promoting a-LA digestion and the formation of satiety-inducing protein fragments.
  • the nutritional, dietary or pharmaceutical composition has a pH value of below 5.5, preferably below 5 and most preferably below 4.6. This may further enhance a sufficient acidity during the a-LA digestion process.
  • Another aspect of the invention therefore relates to a sour milk product comprising a whey fraction comprising a-LA and CMP, wherein the weight ratio between a-LA and GMP in said fraction is > 2.
  • the weight ratio a-LA to CMP is > 3, more preferably > 4.
  • the pH of said sour milk product is below 5,5, preferably below 5 and most preferably below 4.6.
  • Numerous sour milk products can be made by combining milk containing different levels of fat and dry matter with various starter cultures.
  • micro-organisms are added to milk, which is the fermentation substrate. Lactic fermentation is the most important process in the manufacture of sour milk products.
  • the production time and properties of the end product depend on the qualities and activity of the starter culture.
  • a sour milk product according to the invention is readily prepared by supplementing a traditional sour milk product with a suitable source of whey proteins having the desired a-LA/CMP weight ratio. For example, 100 gram of a regular sour milk product (e.g.
  • yoghurt comprises about 1-5 grams milk protein, 80% of which is casein and 20% is whey proteins.
  • the milk product may be supplemented with at least an equal amount by weight (e.g. 1-10 grams/100 gram yoghurt) of a whey protein fraction according to the invention to achieve the desired satiety-inducing effect.
  • a whey fraction comprising a-LA and CMP, wherein the weight ratio between a-LA and GMP is > 2.
  • the sour milk product is selected from the group consisting of fermented milk, buttermilk, stirred yoghurt, set yoghurt, yoghurt drink.
  • a preferred embodiment relates to a satiety-inducing (drinkable) yoghurt.
  • the traditional yoghurt culture comprises Streptococcus thermophilus (Streptococcus salivarius ssp. thermophilus) and Lactobacillus bulgaricus (Lactobacillus delbrueckii ssp. bulgaricus). Both micro-organisms have a symbiotic relationship, i.e. they are mutually beneficial during fermentation.
  • the optimum souring temperature of the yoghurt culture is between 42 and 44°C, and incubation takes around 3 hours until the desired acidity is reached. Both micro-organisms perform better in symbiosis than if grown separately.
  • the pH value of the unsoured milk meets the requirements of the streptococci, so they grow quicker at the start. The increasingly acidic surroundings then favour the lactobacilli, whose pH optimum is under 4.5.
  • the sour milk product is a curded milk product, for instance quark (quarg ), fresh cheese, cottage cheese, cream cheese, kefir, kumyss, viili or ymer.
  • Kefir is a refreshing fermented milk product with a mildly acid taste. Kefir is made by incubating milk with kefir grains or a mother culture made from them.
  • the microflora of the kefir grain and kefir comprise lactic acid bacteria (streptococci, leuconostoc and lactobacillae), yeasts, and possibly acetic acid bacteria.
  • Kefir grains are a complex and specific mix of these micro- organisms and are held together by a polysaccharide matrix.
  • Pasteurised milk is inoculated with the kefir grains for between 18 and 24 hours at 20 to 25°C.
  • the kefir grains are then filtered off.
  • the combined fermentation produces CO2, a small amount of alcohol, and aromatic substances. All together they give the kefir its organoleptically unique taste.
  • Kumyss a refreshing, slightly brisk drink made from mare's milk by lactic and alcoholic fermentation, has been used by the nomadic tribes of Asia for thousands of years. Compared with cow's milk the lower casein content (casein/whey protein 1:1 instead of 4:1 in cow's milk) makes the product runny and the gel softer than Western sour milk products.
  • most kumyss production is concentrated in Russia and Mongolia. Both kumyss and kefir are said to be highly beneficial to health.
  • Ymer produced especially in Denmark, is a sour milk product of increased protein content.
  • the product contains a minimum of 6% protein, 11% non-fat dry matter and 3.5% fat.
  • pasteurised skim milk is incubated with mesophilic mother cultures (starters) at temperatures of between 20 and 25°C until coagulation occurs. It is then gently stirred and heated and the emerging whey removed (up to approx. 50% of the milk volume). Cream is added to adjust the fat content, it is homogenised, cooled and packed. In modern production the dry matter is increased by ultrafiltration.
  • the whey proteins provide a significant amount of the caloric value of the milk product.
  • the whey fraction provides at least 10%, preferably at least 15 or even 25% or more, of the total caloric content of the milk product.
  • the whey fraction contributes to at least 40%, preferably at least 50%, of the total caloric value provided by the proteins of the product
  • the invention also relates to theuse of a whey fraction comprising a- LA and CMP, wherein the weight ratio between a-LA and GMP is > 2 as a satiety-enhancing agent and/or to increase energy expenditure
  • a whey fraction comprising the whey proteins a-lactalbumin (a-LA) and casein macropeptide (CMP), wherein the weight ratio between a-LA and GMP is > 2, as a (satiety-inducing) food additive, preferably as an additive for sour milk products.
  • the (sour) milk product may of course contain one or more additional ingredients that are of benefit for health, in particular gut health.
  • it comprises at least one short (e.g. C2- Cs) chain organic acid or a salt thereof.
  • the organic acid may be selected from the group consisting of lactate, citrate, hydroxycitrate, fumarate, adipate, propionate, acetate, tartarate, succinate and sorbate.
  • the undissociated molecules of these short chain organic acids are in particular active against pathogens in the porte d'entree (place of entry), a process which is concentration- and pH- dependent.
  • a further beneficial ingredient for use in combination with the high a-LA/low CMP whey fraction is a milk oligosaccharide, in particular sialyllactose (3' and/or 6' sialyllactose), which can prevent the adherence of pathogens to the intestinal wall, for instance Gram-negative bacteria, like E.coli , Salmonellae or Enterobacter sakazakii.
  • pathogens for instance Gram-negative bacteria, like E.coli , Salmonellae or Enterobacter sakazakii.
  • the low content of CMP also known to inhibit pathogen adhesion, can be at least partially compensated for.
  • oligopeptides and/or free amino acids such as proline, non- digestible oligosaccharides including prebiotics, in particular FOS and/or GOS, free or conjugated fatty acids, including polyunsaturated fatty acids (PUFAs), such as arachidonic acid (AA), eicosapentaenoic acid (EPA), docosahexaenocic acid (DHA), Gamma-Linolenic Acid (GLA), Dihomogamma Linolenic Acid (DHGLA), stearic acid (SA) and conjugated linolenic acid (CLA).
  • PUFAs polyunsaturated fatty acids
  • AA arachidonic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenocic acid
  • GLA Gamma-Linolenic Acid
  • DHGLA Dihomogamma Linolenic Acid
  • SA stearic acid
  • CLA conjugated
  • a milk product provided herein further comprising at least one polyphenol, preferably selected from the group consisting of epigallocatechin gallate, resveratrol, hydroxytyrosol, oleuropein, polyphenols present in green tea extracts, catechins, polyphenols present in extracts of red grape skin, polyphenols present in olives and/or olive waste water, and their mixtures.
  • Green tea polyphenols of particular interest for the present invention, catechins being most preferred.
  • Green tea polyphenols are known phytochemicals that have antioxidant, anti-micromobial, anticancer, and anti-inflammation properties, and were recently found to promote skin homeostasis and protect against autoimmune diseases. Research shows that green tea can help with weight loss. Extracts of green tea have been used for medicinal purposes for generations in China. Green tea polyphenols in extracts are mostly water-soluble, and can be easily oxidized if they are mixed in emulsions containing water.
  • a high protein yoghurt was prepared, to which as whey proteins were added Hiprotal 60MP or Vivinal Alpha (DOMO, Beilen, The Netherlands). Briefly, the yoghurt milk was pasteurized 1 minute at 85°C and cooled to 43-45°C after which the fermenting bacterial cultures were added. After fermentation to a pH of 4,4 the yoghurt was mixed and subsequently homogenized at 200 bar. Whey proteins were added (4,5 grams per 100 ml) to the homogenized yoghurt. The yoghurt contained 8 % protein in total, of which 3,5 % whole milk proteins and 4,5 % whey-proteins resp. resulting from Hiprotal 60MP and Vivinal.
  • Hiprotal is an ultrafiltrated whey protein powder with as typical analysis 60% protein, 26 % lactose , 6 % minerals, 4,5 % fat and 3,5 % moisture.
  • the whey protein fraction is characterized to comprise 16% CMP and 13 % alfa-lactalbumin so that the ratio a-LA / CMP is about 0.8.
  • Vivinal Alpha has as typical analysis : 72% protein , 12 % fat , 4,5 % minerals , 7 % lactose and 4,5 % moisture.
  • the whey protein-fraction comprises 22 % alfa-lactalbumin and 6 % CMP. Ratio a-LA /CMP 3,6 :1.
  • This Example describes the effect of the addition of either A) a whey protein fraction having an a-LA/CMP ratio ⁇ 1 (whey) or B) a whey protein fraction having an a-LA/CMP ratio >2 to breakfast yoghurt drink on energy expenditure and satiety in humans.
  • Example V The product of example III, but instead of 1% lactose was incorporated 1 % sialyllactose.
  • Skimmed milk was incubated at 28 0 C with a starter culture ⁇ Streptococcus lactis / cremoris and Streptococcus diacetilactis), while rennet was added as well. After 16 hours, a coagulum was formed and a pH value of 4,7 was reached. The coagulum was then stirred thoroughly using a high speed agitator, after which the Quarg (also known as fresh cheese) was heated to 60 0 C for up to 3 minutes and then cooled. Subsequently, the whey was separated in a separator.
  • Quarg also known as fresh cheese
  • Cream and Vivinal Alpha were mixed with the coagulum at a temperature of 8 0 C, after which the product was filled in containers and stored.
  • the Vivinal Alpha can be fully or partially hydrolyzed.
  • Additional ingredients may be added, for instance fruits or parts thereof, seasonings, acidulants, stabilizers, unsaturated organic acids, prebiotics, flavours.
  • Other beneficial additives include those capable of inhibiting the accumulation of (visceral) fat and/or stimulating breakdown of the latter, such as hydroxycitrate, arachidonic acid (AA), pinolenic acid, CLA or green tea extract.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne le domaine des aliments fonctionnels. En particulier, l'invention porte sur des protéines de petit-lait et sur l'utilisation de celles-ci dans des compositions pour la gestion du poids corporel. Il est fourni l'utilisation d'une fraction de petit-lait comprenant les protéines de petit-lait a-lactalbumine (a-LA) et macropeptide de caséine (CMP), le rapport en poids entre a-LA et CMP étant ≥ 2, pour la fabrication d'une composition nutritionnelle, diététique ou pharmaceutique pour favoriser un poids corporel sain. L'invention porte également sur un produit laitier qui comprend une fraction de petit-lait comprenant a-LA et CMP, le rapport en poids entre a-LA et CMP étant ≥ 2.
EP10714380A 2009-04-20 2010-04-20 Produit laitier induisant la satiété Withdrawn EP2421381A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2002768A NL2002768C2 (en) 2009-04-20 2009-04-20 Satiety inducing milk product.
PCT/NL2010/050207 WO2010123351A1 (fr) 2009-04-20 2010-04-20 Produit laitier induisant la satiété

Publications (1)

Publication Number Publication Date
EP2421381A1 true EP2421381A1 (fr) 2012-02-29

Family

ID=41172252

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10714380A Withdrawn EP2421381A1 (fr) 2009-04-20 2010-04-20 Produit laitier induisant la satiété

Country Status (6)

Country Link
EP (1) EP2421381A1 (fr)
CN (1) CN102458135A (fr)
NL (1) NL2002768C2 (fr)
RU (1) RU2011147131A (fr)
SG (1) SG175290A1 (fr)
WO (1) WO2010123351A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20120084A1 (it) * 2012-03-07 2013-09-08 Aboca Spa Societa Agricola Miscela prebiotica.
CN103271156A (zh) * 2013-04-26 2013-09-04 蚌埠市福淋乳业有限公司 含有南瓜子的抹茶酸奶及其制备方法
WO2016108064A1 (fr) * 2014-12-31 2016-07-07 Compagnie Gervais Danone Compositions laitières moussantes
CN106212804B (zh) * 2016-07-25 2023-09-15 统一企业(中国)投资有限公司昆山研究开发中心 乳酸菌风味茶饮料及其制作方法
CN111836555A (zh) 2018-03-07 2020-10-27 菲仕兰坎皮纳荷兰公司 高度可消化的富含蛋白质的营养组合物、其用途及其制备方法
JP7249737B2 (ja) * 2018-03-30 2023-03-31 株式会社明治 発酵乳の製造方法
CN108813262A (zh) * 2018-07-02 2018-11-16 杭州相生相成科技有限公司 一种含dha藻油的复合益生菌固体饮料
CN114557452A (zh) * 2022-03-02 2022-05-31 北京名投营养科技有限公司 一种具有保肝护胃功效的组合物及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010123351A1 *

Also Published As

Publication number Publication date
RU2011147131A (ru) 2013-05-27
WO2010123351A1 (fr) 2010-10-28
CN102458135A (zh) 2012-05-16
SG175290A1 (en) 2011-12-29
NL2002768C2 (en) 2010-10-22

Similar Documents

Publication Publication Date Title
Verruck et al. Dairy foods and positive impact on the consumer's health
Fardet et al. Influence of food structure on dairy protein, lipid and calcium bioavailability: A narrative review of evidence
JP6513629B2 (ja) 乳ベースの製品およびその調製方法
NL2002768C2 (en) Satiety inducing milk product.
Salimei et al. Equid milk for human consumption
Fantuz et al. Macro-and micronutrients in non-cow milk and products and their impact on human health
Korhonen Bioactive milk proteins, peptides and lipids and other functional components derived from milk and bovine colostrum
Barukčić et al. Whey and buttermilk—Neglected sources of valuable beverages
CN107668721A (zh) 包含乳铁蛋白的营养组合物在支持抵抗疾病和状况中的用途
Zervas et al. Goat milk
JP6773562B2 (ja) スフィンゴ脂質吸収促進剤
CN111836555A (zh) 高度可消化的富含蛋白质的营养组合物、其用途及其制备方法
Navamniraj et al. Beneficial impacts of goat milk on the nutritional status and general well-being of human beings: anecdotal evidence.
Saleem et al. Therapeutic potential of popular fermented dairy products and its benefits on human health
Alhaj et al. Milk‐derived bioactive components from fermentation
Perotti et al. Production of functional milk-based beverages
JP6037595B2 (ja) 満腹感誘導組成物及びその製造方法
Nagar et al. Whey: Composition, role in human health and its utilization in preparation of value added products
Tiwari et al. Nutritional Values and Therapeutic Uses of Capra hircus Milk.
JP7263426B2 (ja) 肥満抑制剤
Aktypis et al. Yogurt and health
Yadav et al. Quark cheese: Characteristics, preparation, and recent advances as a functional food
Kaur et al. Role of fermented dairy foods in human health
Frąckiewicz The nutritional and health value of milk and fermented milk drinks®
WO2010023364A1 (fr) Procédé d’amélioration du goût d’un produit

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20111101

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120623